Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03326063 · ClinicalTrials.gov registry record · Phase 2
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT03326063 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 38 participants.
The verdict
NCT03326063, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The overall aim of the study is to determine the efficacy of oral ifetroban, a novel antagonist of T prostanoid (TP) receptors, as a treatment for patients with aspirin-exacerbated respiratory disease (AERD).
Interventions
- DRUG Placebo
- DRUG Ifetroban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2023-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03326063
The ClinicalTrials.gov registry entry for NCT03326063 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03326063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03326063 about?
NCT03326063 is a clinical study titled "Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban". The overall aim of the study is to determine the efficacy of oral ifetroban, a novel antagonist of T prostanoid (TP) receptors, as a treatment for patients with aspirin-exacerbated respiratory disease (AERD).
What is the current status of trial NCT03326063?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2018-04-26. Estimated completion is 2023-04-15.
What interventions are being tested in trial NCT03326063?
The interventions under investigation include: Placebo (DRUG), Ifetroban (DRUG).
Who is sponsoring clinical trial NCT03326063?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.